Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7056726 | 0.90 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL22442113 | 0.89 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL18384672 | 0.86 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL7050573 | 0.82 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL14369633 | 0.82 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL7051399 | 0.81 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL7053236 | 0.80 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL7053234 | 0.80 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL7053230 | 0.80 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL11745737 | 0.79 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2111406-B1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | MERCK SHARP & DOHME (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8093389-B2 | e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases | MERCK SHARP & DOHME CORP. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2111406-A1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | Merck & Co., Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008088688-A1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171761-A1 | Substituted spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | DEVGEN NV (BE) | 2008-02-14 | — | — | US | disclosed |
| EP-1838690-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | Devgen N.V. (BE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006066879-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | DEVGEN N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | KCNA4, HCN4, KCNN4 | PDE4A 419/4885PDE4B 365/4885PDE4C 604/4885 |
| US-20080171761-A1 | Substituted spirochromanone derivatives | CBR3, CBR1, CNKSR1 | PDE4A 4670/4885PDE4B 4699/4885PDE4C 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.